-
IGF2BP1–TUBB4B Signaling in Liver Fibrosis
2026-08-21
The reference study identifies an m6A-dependent IGF2BP1–TUBB4B–FAK pathway that promotes hepatic stellate cell activation, proliferation, and migration. Its combination of transcriptomic re-analysis, RNA-binding and m6A profiling, genetic perturbation, and pharmacological validation provides a useful framework for dissecting methylation-linked mechanisms in liver fibrosis.
-
Acifran: From Receptor Structure to Assay Design
2026-08-20
Acifran is a structurally resolved HCAR2/HCAR3 agonist for lipid metabolism research. This guide translates cryo-EM findings into practical choices for receptor, cAMP, selectivity, and compound-handling assays.
-
DiscoveryProbe Natural Product Library Plus for HTS
2026-08-20
Use the DiscoveryProbe Natural Product Library Plus to connect target-based enzyme assays with cell-based phenotypic and high-content screening. Its pre-dissolved, quality-checked format supports practical hit discovery, while Cryptosporidium AdhE research illustrates how biochemical inhibition can be linked to antiparasitic efficacy.
-
Bone-Penetrating Copper Nanoassembly for Cancer Therapy
2026-08-19
The reference study presents BCB, a baicalein–copper coordinated nanoassembly incorporating a boron-dipyrromethene photosensitizer to combine chemodynamic therapy, photodynamic therapy, and cuproptosis. Its tumor-microenvironment-responsive behavior, bone penetration, and reported 75% cure rate in an irradiated murine melanoma model indicate a strategy for addressing both treatment resistance and poor access to intramedullary tumors.
-
Exendin-4 Workflows for Beta Cell Research
2026-08-19
Exendin-4, also known as Exenatide, connects cAMP signaling to practical beta cell, metabolic, neuronal, and recombinant-expression workflows. This guide translates its documented activity into dose planning, assay controls, yeast-expression validation, and troubleshooting strategies for reproducible type 2 diabetes research.
-
Caspase-8 Fluorometric Assay Kit for Cell Death
2026-08-18
Translate treatment-induced caspase-8 activation into a quantitative fluorescence readout for apoptosis, combination-therapy, and neurodegeneration workflows. This guide connects IETD-AFC assay design with the hyperthermia–cisplatin mechanism reported in recent cancer research.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-08-18
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is appropriate for blunt-ended cloning and sequencing workflows, but not for protocols that require 3′-A overhangs or sticky-end products.
-
Imatinib hydrochloride Research Workflows
2026-08-17
Build more interpretable CML and GIST experiments with a target-aware workflow for Imatinib hydrochloride, from DMSO stock preparation to pathway-resolved validation. A conformational signaling insight from recent p38α research adds a careful mechanistic layer without assuming that every kinase inhibitor has the same phosphatase effect.
-
Carfilzomib (PR-171) Assay Workflows
2026-08-17
A scenario-driven guide to using Carfilzomib (PR-171), SKU A1933, in proteasome, viability, proliferation, and cytotoxicity workflows. It connects formulation controls and orthogonal assay design with recent evidence on apoptosis, endoplasmic reticulum stress, and multimodal cancer-cell death.
-
Dasatinib Monohydrate in CML NET Research
2026-08-16
Dasatinib Monohydrate (BMS-354825) offers a rigorous way to study BCR-ABL-driven leukemia alongside neutrophil extracellular trap biology. This article translates CML NET findings into practical assay-design decisions for resistance, inflammatory, and vascular-toxicity research.
-
E-64 Workflows for Cysteine Protease Research
2026-08-15
E-64 provides irreversible, low-nanomolar cysteine protease inhibition for active-site titration, cathepsin studies, cell-based pathway analysis, and cancer research. This guide translates its biochemical precision into practical workflows and shows how to use it carefully when investigating virus-induced inflammation and necroptosis.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-08-14
The reference study identifies a liver–bone signaling mechanism in which hepatic soluble epoxide hydrolase (sEH) reduces circulating 14,15-EET, suppresses Nrf2-ARE activity, and promotes osteoclast differentiation. By combining clinical samples, ovariectomy-induced osteoporosis, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, the authors connect epoxyeicosatrienoic acid metabolism with redox imbalance and bone loss.
-
Epoxomicin: Selective Proteasome Inhibitor Guide
2026-08-14
Epoxomicin is a selective, irreversible proteasome inhibitor for ubiquitin-proteasome pathway research and protein degradation assays. Its α′,β′-epoxyketone enables covalent inhibition, while supplier-reported biochemical potency and formulation data support controlled experimental use.
-
Annexin V Binding to Endothelial Cells and Thrombin
2026-08-13
The reference study connected recombinant Annexin V binding to cultured endothelial cells with inhibition of surface-dependent factor Xa and thrombin formation. Its central contribution was to show that a phosphatidylserine-binding protein can suppress coagulation on a cellular surface, not only on artificial phospholipid vesicles.
-
Recombinant Human EGF in 3D Spheroid Assays
2026-08-13
Explore how recombinant human EGF can be used as a controlled perturbation in 3D glioblastoma spheroid assays. This guide connects Epidermal Growth Factor biology, product quality, and practical strategies for separating proliferation effects from stemness phenotypes.